A prospective study of 254 colorectal cancer patients receiving oxaliplatin validated the Treatment-induced Neuropathy Assessment Scale (TNAS) and established cutpoints for numbness, sensory symptoms, and interference with daily activities. (Quality of Life Research)
Validated Scale Helps Measure Treatment-Induced Neuropathy in Chinese Patients
The CRC Digest